U.S. markets open in 7 hours 49 minutes

Nabriva Therapeutics plc (NBRV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.3500-0.0200 (-1.46%)
At close: 4:00PM EDT

Nabriva Therapeutics plc

25-28 North Wall Quay
Dublin 1
353 1 649 2000

Full Time Employees72

Key Executives

NameTitlePayExercisedYear Born
Mr. Theodore R. SchroederCEO & Director850.82kN/A1955
Dr. Steven P. GelonePres, COO & Director652.16kN/A1968
Dr. Colin BroomDirector40kN/A1956
Mr. Daniel DolanChief Financial OfficerN/AN/A1977
Mr. Robert L. CrottyGen. Counsel & Sec.N/AN/A1974
Ms. Michele PorrecaChief HR OfficerN/AN/AN/A
Mr. Gary L. SenderConsultantN/AN/A1962
Mr. Werner HeilmayerVP of CMC & IPN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Corporate Governance

Nabriva Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.